Dose-optimised recombinant human thrombopoietin versus eltrombopag in patients with immune thrombocytopenia: a multicenter, randomised controlled trial (The TE-ITP Study)

Authors:

Abstract
No abstract available
Funding Information
  • National Natural Science Foundation of China (82430010)
  • Tianjin science and technology commission (24ZXZSSS00230)
  • Tianjin Municipal Science and Technology Committee
  • CAMS Innovation Fund for Medical Sciences (2023-I2M-2-007)
  • National Major Science and Technology Projects of China (2023ZD0500803)

This publication has 26 references indexed in Scilit: